RemeGen
Disitamab Vedotin(RC48) Plus Tratuzumab(RemeGen)은 HER2 표적 ADC로, HER2-positive Gastric Cancer; HER2-positive Gastroesophageal Junction Adenocarcinoma 영역에서 개발·상용화 중입니다. 작용기전: ADC is revealed to exert its antitumor effect by inducing G2/M arrest and caspase-dependent apoptosis. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 66건의 관련 임상이 등록되어 있습니다. 차별점: novel and robust enzyme-based conjugation technology for developing homogenous ADCs with an improved therapeutic window.
HER2
HER2-positive Gastric Cancer; HER2-positive Gastroesophageal Junction Adenocarcinoma
Recruiting
ADC+ICI) versus gemcitabine/cisplatin (GC) in high-risk upper t
vedotin plus PD-1 blockade and gemcitabine/cisp
linker
novel and robust enzyme-based conjugation technology for developing homogenous ADCs with an improved therapeutic window
ADC is revealed to exert its antitumor effect by inducing G2/M arrest and caspase-dependent apoptosis
payloads, and ADCs, validated using six ADCs (Enhertu, Kadcyla, Trodelvy, RC48, RN927C, and Datroway)
PD-1 blockade and gemcitabine/cisplatin in high
resistance mechanisms, optimize payload delivery, and minimize off-target toxicity
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
RemeGen
Disitamab Vedotin(RC48) Plus Tratuzumab(RemeGen)은 HER2 표적 ADC로, HER2-positive Gastric Cancer; HER2-positive Gastroesophageal Junction Adenocarcinoma 영역에서 개발·상용화 중입니다. 작용기전: ADC is revealed to exert its antitumor effect by inducing G2/M arrest and caspase-dependent apoptosis. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 66건의 관련 임상이 등록되어 있습니다. 차별점: novel and robust enzyme-based conjugation technology for developing homogenous ADCs with an improved therapeutic window.
HER2
HER2-positive Gastric Cancer; HER2-positive Gastroesophageal Junction Adenocarcinoma
Recruiting
ADC+ICI) versus gemcitabine/cisplatin (GC) in high-risk upper t
vedotin plus PD-1 blockade and gemcitabine/cisp
linker
novel and robust enzyme-based conjugation technology for developing homogenous ADCs with an improved therapeutic window
ADC is revealed to exert its antitumor effect by inducing G2/M arrest and caspase-dependent apoptosis
payloads, and ADCs, validated using six ADCs (Enhertu, Kadcyla, Trodelvy, RC48, RN927C, and Datroway)
PD-1 blockade and gemcitabine/cisplatin in high
resistance mechanisms, optimize payload delivery, and minimize off-target toxicity
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.